Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...
In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship ...
Amid the usual hustle before a big medical conference or industry trade show, editors are often buried under a flood of news ...
Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about ...
Psychedelics have demonstrated significant progress, generating enthusiasm across the neuroscience industry and leading to ...
Following the company’s announcement of lackluster results from both its Phase III trials, Novo’s shares dropped nearly 9% pre-market, a significant shift the company hasn’t seen in its shares since ...
Each step in the patient journey, benefit verification, prior authorization, fulfillment, and adherence, creates a potential failure point when systems don’t communicate. In many first-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback